---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-064560"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T03:28:55.010094+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nektar Therapeutics Q2 net loss narrows to $51.1M; cash $409.4M, runway into mid-2026

## Summary
- Net loss $51.1M ($0.27/shr) vs $159.1M loss in Q2 2022; revenue $20.5M vs $21.6M.
- Cash and marketable securities $409.4M, down from $505.0M at Dec 31, 2022; expects to fund ops into mid-2026.
- R&D expense $29.7M (down 30% YoY) due to bempegaldesleukin wind-down; restructuring charges $16.6M.
- Plans Phase 2b study of rezpegaldesleukin in atopic dermatitis; initial data in H1 2025; IND submission in 2024.
- Corrected rezpegaldesleukin efficacy data previously miscalculated by Eli Lilly; evaluating NKTR-255 partnerships.

## SEC filing metadata
- accession: 0001213900-23-064560
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390023064560/0001213900-23-064560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390023064560/ea183032-8k_nektarther.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-064560
- JSON: https://secwatch.observer/filing/0001213900-23-064560.json
- Plain text: https://secwatch.observer/filing/0001213900-23-064560.txt

## Key facts
- Earnings Releases
  NEKTAR THERAPEUTICS reported the second quarter ended June 30, 2023 results: revenue $20.5 million, net income $51.1 million or $0.27 basic and diluted loss per share, EPS $0.27 basic and diluted loss per share.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $20.5 million
  - Net income: $51.1 million or $0.27 basic and diluted loss per share
  - EPS: $0.27 basic and diluted loss per share
  - Result: reported results
  source text: our Phase 2 studies of NKTR-255 in liquid and solid tumors as we evaluate strategic partnership pathways.” Summary of Financial Results Revenue in the second quarter of 2023 was $20.5 million as compared to $21.6 million in the second quarter of 2022. Revenue for the first half of 2023 was $42.1 million as compared to $46.4 million in the first half of 2022. Total
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000121390023064560/0001213900-23-064560-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.